Peer-Reviewed Publications

      Construction of a computable network model of tissue repair and angiogenesis in the lung

      Park, J. S.; Schlage, W. K.; Frushour, B. P.; Talikka, M.; Toedter, G.; Gebel, S.; Deehan, R.; Veljkovic, E.; Westra, J. W.; Peck, M. J.; Boue, S.; Kogel, U.; Gonzalez-Suarez, I.; Hengstermann, A.; Peitsch, M. C.; Hoeng, J.
      Published
      Feb 4, 2013
      DOI
      10.4172/2161-0495.S12-002
      Link to publication
      Topic
      Summary

      We have recently developed methodologies to quantify the biological impact of exposure to environmental toxicants via the use of computable network models and network scoring methods. In this study, we extend our collection of lung pathophysiology specific network models to tissue repair and angiogenesis. It is important to understand the molecular mechanisms of wound healing which, if unresolved, could eventually progress to irreversible disease. The Tissue Repair and Angiogenesis (TRAG) Network consists of nine modular subnetworks that describe the following processes: hypoxia-inducible factor 1 alpha (HIF1A) signaling, sprouting and tubulogenesis, Vascular Endothelial Growth Factor (VEGF)-mediated angiogenesis, growth factor-mediated angiogenesis, immune regulation of angiogenesis, immune regulation of tissue repair, cell migration, differentiation of progenitor cells and fibrosis. We used a data-driven approach to augment the initial literature-based network, and to evaluate a portion of the network using two independent gene expression data sets. This approach increases the confidence in the network’s ability to accurately describe tissue repair processes. The TRAG Network serves as a valuable research tool for assessing the biological impact of exposure to environmental insults and in understanding the initial molecular events that may lead to disease. The TRAG network, which consists of 666 nodes linked by 1215 relationships or edges covering 1371 PubMed IDs, is expressed in the Biological Expression Language and made available in computer readable formats including XGMML and .xls.

      PMIScience.com is operated by Philip Morris International for the purpose of publishing and disseminating scientific information about Philip Morris International’s efforts in support of its smoke-free product portfolio. This site is a global site for use by scientists, the public health and regulatory communities, and other stakeholders with an interest in tobacco policy. The purpose of this site is not advertising or marketing, nor is it directed at any specific market. It is not intended for use by consumers. New tobacco products sold in the United States are subject to FDA regulation; therefore the content of this site is not intended to make, and nor should it be construed as making, any product related claims in the United States without proper FDA authorization. ​
      ​
      Reduced Risk Products ("RRPs”) is the term we use to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continuing smoking. PMI has a range of RRPs in various stages of development, scientific assessment and commercialization. All of our RRPs are smoke-free products that deliver nicotine with far lower quantities of harmful and potentially harmful constituents than found in cigarette smoke.